Evidence map›Paper›PMID 41501378›Full record

ArticleCommunications biology2026

Enhancing the breadth of protection in mice with a multivalent influenza vaccine.

Xiang Wang, Yixin Niu, Ying Hu, Caihong Zhu, Xi Yang, Hongyang Shi, Yao Yan, Ping Zhou, Longfei Ding, Miaomiao Zhang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Xiang WangShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yixin NiuShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Ying HuShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Caihong ZhuShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Xi YangShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Hongyang ShiDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Yao YanShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Ping ZhouDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Longfei DingShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Miaomiao ZhangShanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Mangteng WuInstitute of Neuroscience, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
Shubing TangDepartment of Investigational New Drug, Shanghai Reinovax Biologics Co., Ltd, Shanghai, China.
Man XingDepartment of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China. xingman@tmu.edu.cn.ORCID http://orcid.org/0000-0002-6076-2547
Dongming ZhouShanghai Public Health Clinical Center, Fudan University, Shanghai, China. zhoudongming@tmu.edu.cn.ORCID http://orcid.org/0000-0002-5989-7591

Funding

National Natural Science Foundation of China (National Science Foundation of China) 82241065National Natural Science Foundation of China (National Science Foundation of China) 82302061
6 · The paper itself

Abstract

The high mutation rate of the influenza virus poses a significant challenge to global health, highlighting the urgent need for broad-spectrum vaccines. Here, we engineered Ad-Hex, a pan-influenza vaccine comprising three chimpanzee adenoviral vectors (Ad-H1H3, Ad-BYBV, and Ad-H5H7), each encoding the hemagglutinin (HA) genes from two distinct influenza virus subtypes/lineages in the △E1 region. A single intranasal dose of Ad-Hex induced robust humoral, cellular, and mucosal immunity, conferring complete protection against lethal challenge with six vaccine-matched strains in female C57BL/6 or Balb/c mice. Notably, the vaccine achieved 60% survival rates against mismatched strains. Mechanistic studies revealed that Ad-Hex activated germinal center B-cell responses not only against the cognate HAs but also against the conserved HA stalks. This drove the production of cross-reactive antibodies, which contributed to heterologous protection along with the CD8

Indexed as

Influenza VaccinesOrthomyxoviridae InfectionsAdenoviridaeAnimalsAntibodies, ViralFemaleGenetic VectorsHemagglutinin Glycoproteins, Influenza VirusMiceMice, Inbred BALB CMice, Inbred C57BLAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza Vaccines

Identifiers

PMID41501378
PMCPMC12876894

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.